Table 1. Identification of drug candidates for DEGs in RIAs.
| MOA | Perturbagen count | Perturbagen ID | Name |
|---|---|---|---|
| MEK inhibitor | 5 | BRD-K89014967, BRD-K49865102, BRD-K05104363, BRD-K57080016, BRD-K62810658 | AS-703026, PD-0325901, PD-184352, selumetinib, PD-98059 |
| p38 MAPK inhibitor | 3 | BRD-K77133231, BRD-K54330070, BRD-K52751261 | PD-169316, SB-202190, TAK-715 |
| HSP inhibitor | 2 | BRD-K51967704, BRD-K41859756 | BIIB021, NVP-AUY922 |
| FLT3 inhibitor | 2 | BRD-K12502280, BRD-K23192422 | TG-101348, lestaurtinib |
| SRC inhibitor | 2 | BRD-K47598052, BRD-K19540840 | PP-1, saracatinib |
| ABL inhibitor | 2 | BRD-K41337261, BRD-K99964838 | ZM-306416, bosutinib |
| RAF inhibitor | 2 | BRD-K01253243, BRD-K30677119 | SB-590885, PP-30 |
| IKK inhibitor | 1 | BRD-K51575138 | TPCA-1 |
| Phenylalanyl tRNA synthetase inhibitor | 1 | BRD-K39944607 | Ochratoxin-a |
| JNK inhibitor | 1 | BRD-K84085265 | CG-930 |
| VEGFR inhibitor | 1 | BRD-K53414658 | tivozanib |
| MTOR inhibitor | 1 | BRD-K67566344 | KU-0063794 |
| Glycogen synthase kinase inhibitor | 1 | BRD-K94176593 | TWS-119 |
| HMGCR inhibitor | 1 | BRD-U88459701 | Atorvastatin |
| Gonadotropin releasing factor hormone receptor agonist | 1 | BRD-A62434282 | Goserelin |
| Histone lysine methyltransferase inhibitor | 1 | BRD-K74236984 | UNC-0321 |
| Calcium channel blocker | 1 | BRD-K49404994 | Levetiracetam |
| Chelating agent | 1 | BRD-K07265709 | Razoxane |
| TGF beta receptor inhibitor | 1 | BRD-K06234293 | LY-364947 |
| Cyclooxygenase inhibitor | 1 | BRD-A22844106 | Tenoxicam |
| PI3K inhibitor | 1 | BRD-K06750613 | GSK-1059615 |
| BCR-ABL kinase inhibitor | 1 | BRD-K49328571 | Dasatinib |
| CHK inhibitor | 1 | BRD-K46056750 | AZD-7762 |
DEGs, differentially expressed genes; RIA, ruptured intracranial aneurysm; MOA, CMap mode of action.